Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.

[1]  C. Zarate,et al.  Ketamine treatment for depression: a review , 2022, Discover Mental Health.

[2]  W. Drevets,et al.  Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al. , 2022, Molecular Psychiatry.

[3]  B. Mulsant,et al.  Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults , 2021, JAMA network open.

[4]  T. Lumley,et al.  Blinding and expectancy confounds in psychedelic randomized controlled trials , 2021, Expert review of clinical pharmacology.

[5]  M. Michaelides,et al.  Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability , 2021, Molecular Psychiatry.

[6]  C. Zarate,et al.  Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. , 2020, Journal of affective disorders.

[7]  C. Loo,et al.  Intravenous arketamine for treatment-resistant depression: open-label pilot study , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[8]  C. Loo,et al.  Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. , 2019, Journal of affective disorders.

[9]  M. Fava,et al.  Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) , 2019, The international journal of neuropsychopharmacology.

[10]  S. Thompson,et al.  (R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses , 2019, British journal of pharmacology.

[11]  Yuko Fujita,et al.  Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine , 2019, Pharmacology Biochemistry and Behavior.

[12]  R. Shelton,et al.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.

[13]  J. Talbot,et al.  Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. , 2019, The American journal of psychiatry.

[14]  D. Rujescu,et al.  Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study , 2018, Acta psychiatrica Scandinavica.

[15]  P. Ryan,et al.  Finding factors that predict treatment‐resistant depression: Results of a cohort study , 2018, Depression and anxiety.

[16]  K. Hashimoto,et al.  (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice , 2018, Neuropsychopharmacology.

[17]  W. Drevets,et al.  Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. , 2018, The American journal of psychiatry.

[18]  R. Shelton,et al.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial , 2017, JAMA psychiatry.

[19]  K. Hashimoto,et al.  (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine , 2017, Biological Psychiatry.

[20]  K. Hashimoto,et al.  Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[21]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[22]  K. Hashimoto,et al.  Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression , 2016, Psychopharmacology.

[23]  K. Hashimoto,et al.  Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine , 2016, Psychiatry Research.

[24]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[25]  R. Shelton,et al.  A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.

[26]  J. Dilger,et al.  Ketamine enantiomers in the rapid and sustained antidepressant effects , 2016, Therapeutic advances in psychopharmacology.

[27]  K. Hagi,et al.  Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories , 2016, Psychological Medicine.

[28]  T. Furukawa,et al.  Ketamine and other glutamate receptor modulators for depression in adults , 2015, BJPsych Advances.

[29]  K. Hashimoto,et al.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects , 2015, Translational Psychiatry.

[30]  D. Charney,et al.  A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder , 2014, Biological Psychiatry.

[31]  R. Lam,et al.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes , 2014, Psychological Medicine.

[32]  K. Hashimoto,et al.  R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine , 2014, Pharmacology Biochemistry and Behavior.

[33]  Julien Mendlewicz,et al.  Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. , 2007, The Journal of clinical psychiatry.

[34]  E. Giller,et al.  Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports , 2003, Neuropsychopharmacology.

[35]  P. Amorim.  Mini International Neuropsychiatric Interview (MINI): validacao de entrevista breve para diagnostico de transtornos mentais , 2000 .

[36]  F. M. Borgbjerg,et al.  Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. , 1997, European journal of pharmacology.

[37]  K. L. Leenders,et al.  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) , 1997, European Neuropsychopharmacology.

[38]  I. Øye,et al.  Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain , 1995, Pain.

[39]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[40]  D. Chernik,et al.  Validity and Reliability of the Observer's: Assessment of Alertness/Sedation Scale Study with Intravenous Midazolam , 1990, Journal of clinical psychopharmacology.

[41]  P. White,et al.  Pharmacology of Ketamine Isomers in Surgical Patients , 1980, Anesthesiology.

[42]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[43]  S. Southwick,et al.  Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.

[44]  Hélio Elkis,et al.  Traduçao e adaptaçao de um instrumento de avaliaçao psicopatológica das psicoses: a Escala breve de avaliaçao psiquiátrica-versao ancorada (BPRS-A) , 1996 .